Crafton Biotechnology

What Crafton Biotechnology does

Crafton Biotechnology is a Nagoya, Japan-based biotechnology company founded in March 2022 that develops enabling chemistries and a drug discovery platform for high-purity mRNA therapeutics. Its flagship technology is PureCap®, a proprietary mRNA capping analog that uses a hydrophobic tag to enable purification of cap-structured mRNA via reverse-phase HPLC, yielding native-type mRNA with low immunogenicity that supports dose reduction. The company has also developed a novel UV-cleavable phosphoramidite reagent (2-Cyanoethyl [2,2-dimethyl-1-(2-nitrophenyl)propyl] N,N-Diisopropylphosphoramidite) for efficient synthesis of 5'-phosphorylated RNA, addressing a key bottleneck in next-generation mRNA therapeutic manufacturing. Both technologies originate from research at Nagoya University and the Institute of Science Tokyo, and the company is headquartered in the Nagoya University Incubation Facility.

The company's customers are pharmaceutical and biotechnology companies developing mRNA-based vaccines, cancer immunotherapies, and genetic disease treatments, as well as academic and research institutions engaged in mRNA drug discovery. Crafton monetizes through three streams: licensing of its proprietary chemistries (notably the phosphoramidite reagent, licensed to FUJIFILM Wako Pure Chemical Corporation for global manufacturing and commercialization starting May 2026), joint research and co-development agreements (e.g., FunPep Co., Ltd. for therapeutic mRNA vaccines combining antibody-inducing peptides with Crafton's mRNA platform), and technology transfer to pharmaceutical and research partners. Pricing is quote-based with no public disclosure, consistent with B2B biotech commercial practice. The company operates with 11-50 employees, is privately held, and is led by a recently assembled executive team (Hayato Watanabe, CEO; Kelvin Chan, CTO/CBO; Tadashi Umemoto, CCO) installed during 2024-2025 to drive commercialization of the academic IP.

Name

Crafton Biotechnology

Legal name

Crafton Biotechnology株式会社

Website

https://craftonbio.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Crafton Biotechnology is a Nagoya-based biotech startup developing proprietary mRNA capping chemistry (PureCap®) and a UV-cleavable phosphoramidite reagent to enable high-purity, low-immunogenicity mRNA therapeutics for pharmaceutical, biotech, and academic customers worldwide.

Ownership category

akta.pro rank

Product category

mRNA Therapeutics Development

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industries

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• MRNA capping technology
• Nucleic acid reagents
• MRNA drug discovery
• Phosphoramidite synthesis
• Biotechnology platform

Headquarters

HQ city

Nagoya

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Licensing of Proprietary Chemistries: Crafton licenses its proprietary phosphoramidite reagent technology to FUJIFILM Wako Pure Chemical Corporation for global manufacturing and commercialization for research use. Revenue is generated through licensing fees and royalties from product sales.
2. Joint Research & Development Services: Co-development agreements with pharmaceutical companies and biotech partners such as FunPep Co., Ltd. for therapeutic mRNA vaccine development. Revenue is generated through research collaboration funding and milestone payments.
3. Technology Transfer: Transfer of mRNA platform technologies to pharmaceutical companies and research institutions for drug discovery and development.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Crafton Biotechnology develops and commercializes proprietary mRNA synthesis chemistries — primarily its PureCap® co-transcriptional capping analog and a novel UV-cleavable phosphoramidite reagent — that enable production of high-purity, low-immunogenicity cap-structured mRNA for therapeutic and vaccine applications. The company monetizes these chemistries through research reagent sales via FUJIFILM Wako, licensing agreements, and joint research collaborations with pharmaceutical and biotech partners developing mRNA vaccines for cancer, infectious disease, and genetic disorders.

Product overview

Crafton Biotechnology operates as a biotech company built around its proprietary mRNA technology platform. The core offering consists of the PureCap® capping analog technology, which enables high-purity mRNA synthesis through a proprietary hydrophobic tagging strategy. The company also commercializes a novel phosphoramidite reagent for 5'-phosphorylated RNA synthesis. These technologies are offered through research reagent sales and partnerships with pharmaceutical companies for drug discovery and development services, including joint research programs for therapeutic mRNA vaccines.

Differentiator

Problem solved

Functional benefit

Products and services

• PureCap® Capping Technology Proprietary capping analog technology that enables co-transcriptional synthesis of high-purity cap-structured mRNA with a hydrophobic tag for efficient purification via reverse-phase HPLC, producing native-type mRNA with low immunogenicity. Designed for pharmaceutical companies, biotech firms, and academic researchers developing mRNA vaccines and therapeutics.
• Novel Phosphoramidite Reagent (2-Cyanoethyl [2,2-dimethyl-1-(2-nitrophenyl)propyl] N,N-Diisopropylphosphoramidite) A UV-cleavable phosphoramidite reagent for introducing 5'-phosphate groups into RNA and oligonucleotide sequences, enabling efficient synthesis of high-purity 5'-monophosphorylated RNA via reverse-phase chromatography. Designed for research use in nucleic acid synthesis applications supporting next-generation mRNA therapeutics including cancer vaccines and genetic disease treatments.
• mRNA Drug Discovery Platform Comprehensive mRNA technology platform enabling design, synthesis, and development of high-quality mRNA drugs and vaccines for infectious diseases, rare genetic disorders, and regenerative medicine applications. Built around PureCap® capping technology and proprietary phosphoramidite chemistries.

Quantifiable outcome

• PureCap®-synthesized mRNA achieves high purity and low immunogenicity, enabling dose reduction and decreased side effects
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core.

• FunPep Co., Ltd. (株式会社ファンペップ)coreStrategic or Co-development Partner · 1 June 2026Crafton and FunPep Co., Ltd. entered a joint research agreement to develop therapeutic mRNA vaccines combining FunPep's antibody-inducing peptide technology with Crafton's proprietary mRNA platform (including PureCap®). Crafton is responsible for mRNA vaccine synthesis while FunPep handles efficacy evaluation. The collaboration aims to create a novel modality by combining both companies' proprietary foundation technologies.
• FUJIFILM Wako Pure Chemical Corporation (富士フイルム和光純薬)coreChannel Partner/ Reseller/ Distributor · 18 May 2026Crafton entered a licensing agreement with FUJIFILM Wako Pure Chemical Corporation for the manufacturing and global commercialization of Crafton's novel phosphoramidite reagent for high-purity mRNA synthesis. FUJIFILM Wako manufactures and distributes the reagent for research use starting May 20, 2026. This partnership is key to Crafton's strategy of expanding access to its enabling chemistries globally.
• Nagoya University (名古屋大学)coreTechnology or Integration · 1 March 2022Crafton Biotechnology was founded based on technology developed at Nagoya University and is headquartered at the Nagoya University Incubation Facility. The company's core PureCap® technology originates from Nagoya University research, establishing a foundational academic-technology partnership.
• Institute of Science Tokyo (東京科学大学)coreTechnology or Integration · 1 March 2022Crafton Biotechnology was founded based on technology developed at Institute of Science Tokyo (formerly Tokyo Institute of Technology). The company maintains active partnerships with the university for technology development and talent, and won the Special Jury Prize at the Institute's certified venture contest IOI & SS 2025.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• TriLink BioTechnologies (Maravai LifeSciences): TriLink is a leading mRNA reagent and CDMO provider, best known for its CleanCap® capping technology. It is the closest direct competitor to Crafton's PureCap® platform, addressing the same mRNA capping bottleneck with a commercialized, industry-standard solution.
• New England Biolabs: NEB is a major supplier of enzymes and reagents for RNA synthesis, including the mRNA capping enzyme (Vaccinia capping system) widely used in mRNA manufacturing. It competes directly with Crafton's chemical capping approach as an alternative enabling tool.
• Aldevron (Danaher): Aldevron supplies high-quality nucleic acids, including plasmid DNA and mRNA, to therapeutic developers. As a CDMO/reagent provider in the mRNA supply chain, it competes with Crafton's chemistry platform and serves the same biopharma customer base.

Broad incumbents

• Moderna: Moderna is the global leader in mRNA therapeutics with full vertical integration across capping chemistry, manufacturing, and drug development. It is the dominant incumbent whose internal technology decisions set the bar for third-party capping reagents.
• BioNTech: BioNTech is a major mRNA therapeutics company developing cancer vaccines and infectious disease vaccines using its proprietary mRNA platform. As a broad incumbent, it competes with Crafton's therapeutic mRNA ambitions and is a potential licensor/customer of capping chemistry.
• CureVac: CureVac is an early pioneer in mRNA therapeutics with proprietary RNA optimization and capping chemistry. It competes in the same therapeutic mRNA category as Crafton and serves as a benchmark for advanced-platform mRNA developers.

Emerging players

• Arcturus Therapeutics: Arcturus is an emerging clinical-stage mRNA therapeutics company developing vaccines and rare disease therapies using its STARR® and LUNAR® platforms. Comparable to Crafton as a smaller, platform-driven mRNA player, though further along clinically.
• Strand Therapeutics: Strand is an emerging mRNA therapeutics company developing programmable, self-replicating mRNA for cancer and beyond. As a smaller, platform-based mRNA developer, it is thematically comparable to Crafton's stage and ambition.

Regional players

• Daiichi Sankyo: Daiichi Sankyo is a leading Japanese pharma with growing investment in nucleic acid and mRNA-based therapeutics. As a large Japanese player in the same disease areas (oncology, vaccines), it is a potential acquirer/partner for Crafton.
• FUJIFILM Diosynth Biotechnologies: FUJIFILM Diosynth is the CDMO arm of the FUJIFILM group (parent/sibling to FUJIFILM Wako, Crafton's distribution partner). It provides mRNA and viral vector CDMO services and is a comparable infrastructure peer in the same group ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crafton Biotechnology